
    
      Phase IV, open-label, non comparative, multicenter, previously treated patients (PTP)
      clinical trial. Patients with severe or moderate hemophilia B with baseline levels of plasma
      factor IX < 5% activity will participate in this study for both treatment regimens: "on
      demand" therapy for acute bleeding episodes and therapy for prophylaxis of bleeding episodes
      ( "Short-term therapy")*.

      * Short-Term Therapy: Prophylactic therapy given before surgery, including dental procedures,
      prior to a event that would likely result in bleeding ( sports, exercise, or heavy work), as
      well as to prevent further bleeds into a target joint). This short-term therapy for
      intermittent secondary therapy.
    
  